Pacira BioSciences (PCRX) Depreciation & Amortization (CF) (2010 - 2026)

Pacira BioSciences' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $21.3 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 0.77% year-over-year to $21.3 million; the TTM figure through Mar 2026 stood at $91.2 million (up 11.85% YoY), while the FY2025 annual figure was $91.0 million, up 15.53% from the prior year.
• Depreciation & Amortization (CF) was $21.3 million for Q1 2026 at Pacira BioSciences, roughly flat from $21.3 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $30.4 million in Q4 2022 to a low of $18.4 million in Q1 2024.
• Historically, Depreciation & Amortization (CF) has averaged $21.1 million across 5 years, with a median of $20.3 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) jumped 326.06% in 2022, then tumbled 39.21% in 2023.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $30.4 million in 2022, then sank by 39.21% to $18.5 million in 2023, then grew by 14.92% to $21.2 million in 2024, then grew by 0.47% to $21.3 million in 2025, then slipped by 0.05% to $21.3 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $21.3 million (Q1 2026), $21.3 million (Q4 2025), and $21.2 million (Q3 2025), per Business Quant data.